Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for patients with cancer and autoimmune diseases who have unmet medical needs. The company utilizes its protein engineering capabilities to design new technologies and XmAb drug candidates with improved properties and multi-target mechanisms of action. Xencor advances these candidates into clinical-stage development, conducting Phase 1 and Phase 2 studies for a broad portfolio of programs. The company's protein design approach involves engineering Fc domains, which are parts of antibodies that interact with the immune system and control antibody structure. These engineered Fc domains, which are constant and interchangeable across antibodies, provide specific features such as bispecific structure and extended half-life, serving as scaffolds for XmAb drug candidates. Xencor and its partners develop XmAb antibodies and other biotherapeutic drug candidates with improved properties and functionality. Applications of their protein engineering technologies include multi-specific antibodies that engage two or more targets simultaneously, enhancing antibody performance by increasing immune inhibitory activity, improving cytotoxicity, extending circulating half-life, and stabilizing novel protein structures. Three marketed medicines have been developed using Xencor's XmAb protein engineering technologies. The company's modular approach to protein engineering allows for the design of multiple XmAb drug candidates with distinct and novel mechanisms of action. Xencor's business, research, and clinical efforts are focused on developing and advancing a portfolio of XmAb drug candidates in oncology and autoimmune diseases.